Next Article in Journal
Cold Atmospheric Plasma Treatment of Chondrosarcoma Cells Affects Proliferation and Cell Membrane Permeability
Previous Article in Journal
An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics
Previous Article in Special Issue
n–3 Polyunsaturated Fatty Acid Amides: New Avenues in the Prevention and Treatment of Breast Cancer
Open AccessArticle

The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors

Department of Physiological Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences -SGGW, Nowoursynowska 159, 02-776 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(7), 2292; https://doi.org/10.3390/ijms21072292
Received: 27 January 2020 / Revised: 23 March 2020 / Accepted: 24 March 2020 / Published: 26 March 2020
(This article belongs to the Special Issue Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches)
Crosstalk between neoplastic and immune cells in the tumor microenvironment (TME) influences the progression of disease in human and canine cancer patients. Given that canine mammary tumors are a useful model to study breast cancer biology, we aimed to evaluate the expression of genes associated with T lymphocyte activity in benign, malignant, and metastatic canine mammary tumors. Interestingly, metastatic tumors exhibit increased expression of CXCR3, CCR2, IL-4, IL-12p40, and IL-17. In particular, we focused on IL-17, a key interleukin associated with the Th17 lymphocyte phenotype. Th17 cells have been shown to play a contradictory role in tumor immunity. Although IL-17 showed a high expression in the metastatic tumors, the expression of RORγt, a crucial transcription factor for Th17 differentiation was barely detected. We further investigated IL-17 expression using immunohistochemistry, through which we confirmed the increased expression of this interleukin in malignant and metastatic mammary tumors. Finally, we compared the plasma levels of IL-17 in healthy and malignant mammary tumor-bearing dogs using ELISA but found no differences between the groups. Our data indicate that the IL-17 in metastatic tumors may be produced by other cell types, but not by Th17 lymphocytes. Overall, our results broaden the available knowledge on the interactions in canine mammary tumors and provide insight into the development of new therapeutic strategies, with potential benefits for human immune oncology. View Full-Text
Keywords: breast cancer model; interleukin-17; Th17 cells; co-inhibitory ligands; immune checkpoints; inflammatory cytokines; chemokine receptors; tumor-associated macrophages; cancer immunotherapy breast cancer model; interleukin-17; Th17 cells; co-inhibitory ligands; immune checkpoints; inflammatory cytokines; chemokine receptors; tumor-associated macrophages; cancer immunotherapy
Show Figures

Graphical abstract

MDPI and ACS Style

Bujak, J.K.; Szopa, I.M.; Pingwara, R.; Kruczyk, O.; Krzemińska, N.; Mucha, J.; Majchrzak-Kuligowska, K. The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors. Int. J. Mol. Sci. 2020, 21, 2292.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop